Addex Therapeutics (ADXN.SW) Stock Price

Addex Therapeutics Price

SIX·CLOSED
0.04CHF-0.0012 (-3.02 %)
Market closed

Revenue at Addex Therapeutics has contracted by 13.3% per year over the past 19 years to 410,000.00 CHF. For Addex Therapeutics, the net margin of 1,720.9% is up versus -331.5% a few years ago. The consensus 12-month price target for Addex Therapeutics is 0.16 CHF, about 316.3% above where the stock trades today. Of 10 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 12% above its 52-week low.

Addex Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Addex Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Addex Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Addex Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Addex Therapeutics Stock Price History
DateAddex Therapeutics Price
8/14/20260.04 CHF
8/13/20260.04 CHF
8/12/20260.04 CHF
8/11/20260.04 CHF
8/10/20260.04 CHF
8/7/20260.04 CHF
8/6/20260.04 CHF
8/5/20260.04 CHF
8/4/20260.04 CHF
7/31/20260.04 CHF
7/30/20260.04 CHF
7/29/20260.04 CHF
7/28/20260.04 CHF
7/27/20260.04 CHF
7/24/20260.04 CHF
7/23/20260.04 CHF
7/22/20260.04 CHF
7/21/20260.04 CHF
7/20/20260.04 CHF
7/17/20260.04 CHF
7/15/20260.04 CHF
7/14/20260.04 CHF
7/13/20260.04 CHF
7/10/20260.04 CHF
7/9/20260.04 CHF
7/8/20260.04 CHF
7/7/20260.04 CHF
7/6/20260.04 CHF
7/3/20260.04 CHF
7/2/20260.04 CHF
7/1/20260.04 CHF
6/30/20260.04 CHF
6/29/20260.04 CHF
6/26/20260.04 CHF
6/25/20260.04 CHF
6/24/20260.04 CHF
6/23/20260.05 CHF
6/22/20260.04 CHF
6/19/20260.05 CHF
6/18/20260.04 CHF
6/17/20260.04 CHF
6/16/20260.04 CHF
6/15/20260.05 CHF
6/12/20260.04 CHF
6/11/20260.05 CHF
6/10/20260.05 CHF
6/9/20260.05 CHF
6/8/20260.04 CHF
6/5/20260.05 CHF
6/4/20260.05 CHF
6/3/20260.05 CHF
6/2/20260.05 CHF
6/1/20260.05 CHF
5/29/20260.05 CHF
5/28/20260.05 CHF
5/27/20260.05 CHF
5/26/20260.05 CHF
5/22/20260.05 CHF
5/21/20260.05 CHF
5/20/20260.05 CHF
5/19/20260.05 CHF
5/18/20260.05 CHF
5/15/20260.05 CHF
5/13/20260.05 CHF
5/12/20260.05 CHF
5/11/20260.05 CHF
5/8/20260.05 CHF
5/7/20260.05 CHF
5/6/20260.05 CHF
5/5/20260.05 CHF
5/4/20260.05 CHF
4/30/20260.05 CHF
4/29/20260.05 CHF
4/28/20260.05 CHF
4/27/20260.05 CHF
4/24/20260.05 CHF
4/23/20260.05 CHF
4/22/20260.05 CHF
4/21/20260.05 CHF
4/20/20260.04 CHF
4/17/20260.04 CHF
4/16/20260.05 CHF
4/15/20260.05 CHF
4/14/20260.05 CHF
4/13/20260.05 CHF
4/10/20260.05 CHF
4/9/20260.05 CHF
4/8/20260.04 CHF
4/7/20260.04 CHF
4/2/20260.04 CHF
4/1/20260.04 CHF
3/31/20260.04 CHF
3/30/20260.04 CHF
3/27/20260.04 CHF
3/26/20260.04 CHF
3/25/20260.04 CHF
3/24/20260.04 CHF
3/23/20260.04 CHF
3/20/20260.04 CHF
3/19/20260.04 CHF
3/18/20260.04 CHF
3/17/20260.05 CHF
3/16/20260.04 CHF
3/13/20260.05 CHF
3/12/20260.04 CHF
3/11/20260.05 CHF
3/10/20260.05 CHF
3/9/20260.05 CHF
3/6/20260.05 CHF
3/5/20260.05 CHF
3/4/20260.05 CHF
3/3/20260.05 CHF
3/2/20260.05 CHF
2/27/20260.05 CHF
2/26/20260.05 CHF
2/25/20260.05 CHF
2/24/20260.05 CHF
2/23/20260.05 CHF
2/20/20260.05 CHF
2/19/20260.05 CHF
2/18/20260.05 CHF
2/17/20260.05 CHF
2/16/20260.05 CHF
2/13/20260.05 CHF
2/12/20260.05 CHF
2/11/20260.05 CHF
2/10/20260.05 CHF
2/9/20260.05 CHF
2/6/20260.05 CHF
2/5/20260.05 CHF
2/4/20260.05 CHF
2/3/20260.05 CHF
2/2/20260.05 CHF
1/30/20260.05 CHF
1/29/20260.05 CHF
1/28/20260.05 CHF
1/27/20260.05 CHF
1/26/20260.05 CHF
1/23/20260.06 CHF
1/22/20260.05 CHF
1/21/20260.05 CHF
1/20/20260.05 CHF
1/19/20260.05 CHF
1/16/20260.05 CHF
1/15/20260.05 CHF
1/14/20260.06 CHF
1/13/20260.05 CHF
1/12/20260.06 CHF
1/9/20260.06 CHF
1/8/20260.06 CHF
1/7/20260.05 CHF
1/6/20260.05 CHF
1/5/20260.05 CHF
12/30/20250.06 CHF
12/29/20250.06 CHF
12/23/20250.06 CHF
12/22/20250.05 CHF
12/19/20250.06 CHF
12/18/20250.06 CHF
12/17/20250.05 CHF
12/16/20250.05 CHF
12/15/20250.05 CHF
12/12/20250.06 CHF
12/11/20250.06 CHF
12/10/20250.05 CHF
12/9/20250.05 CHF
12/8/20250.05 CHF
12/5/20250.05 CHF
12/4/20250.05 CHF
12/3/20250.05 CHF
12/2/20250.06 CHF
12/1/20250.06 CHF
11/28/20250.06 CHF
11/27/20250.06 CHF
11/26/20250.05 CHF
11/25/20250.05 CHF
11/24/20250.05 CHF
11/21/20250.05 CHF
11/20/20250.06 CHF
11/19/20250.06 CHF
11/18/20250.06 CHF
11/17/20250.06 CHF
11/14/20250.06 CHF
11/13/20250.06 CHF
11/12/20250.06 CHF
11/11/20250.06 CHF
11/10/20250.06 CHF
11/7/20250.06 CHF
11/6/20250.06 CHF
11/5/20250.06 CHF
11/4/20250.06 CHF
11/3/20250.06 CHF
10/31/20250.06 CHF
10/30/20250.06 CHF
10/29/20250.06 CHF
10/28/20250.06 CHF
10/27/20250.06 CHF
10/24/20250.06 CHF
10/23/20250.06 CHF
10/22/20250.06 CHF
10/21/20250.06 CHF
10/20/20250.06 CHF
10/17/20250.06 CHF
10/16/20250.06 CHF
10/15/20250.06 CHF
10/14/20250.06 CHF
10/13/20250.06 CHF
10/10/20250.06 CHF
10/9/20250.06 CHF
10/8/20250.06 CHF
10/7/20250.07 CHF
10/6/20250.06 CHF
10/3/20250.06 CHF
10/2/20250.06 CHF
10/1/20250.06 CHF
9/30/20250.06 CHF
9/29/20250.06 CHF
9/26/20250.06 CHF
9/25/20250.07 CHF
9/24/20250.07 CHF
9/23/20250.07 CHF
9/22/20250.07 CHF
9/19/20250.06 CHF
9/18/20250.07 CHF
9/17/20250.07 CHF
9/16/20250.07 CHF
9/15/20250.07 CHF
9/12/20250.07 CHF
9/11/20250.06 CHF
9/10/20250.06 CHF
9/9/20250.06 CHF
9/8/20250.05 CHF
9/5/20250.06 CHF
9/4/20250.06 CHF
9/3/20250.05 CHF
9/2/20250.06 CHF
9/1/20250.06 CHF
8/29/20250.06 CHF
8/28/20250.06 CHF
8/27/20250.06 CHF
8/26/20250.06 CHF
8/25/20250.06 CHF
8/22/20250.06 CHF
8/21/20250.05 CHF
8/20/20250.06 CHF
8/19/20250.06 CHF
8/18/20250.06 CHF
Access this data via the Eulerpool API
Get Free API Key

Addex Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
1.45 M CHF
-20.52 M CHF
-20.80 M CHF
Jan 1, 2023
1.62 M CHF
-2.24 M CHF
-10.56 M CHF
Jan 1, 2024
410,000.00 CHF
-2.76 M CHF
7.06 M CHF
Jan 1, 2025 (e)
765,000.00 CHF
-3.30 M CHF
-7.01 M CHF
Jan 1, 2026 (e)
765,000.00 CHF
-3.33 M CHF
-4.00 M CHF
Jan 1, 2027 (e)
0.00 CHF
-3.16 M CHF
0.00 CHF
Jan 1, 2028 (e)
0.00 CHF
-2.55 M CHF
-3.87 M CHF
Jan 1, 2029 (e)
0.00 CHF
-2.55 M CHF
0.00 CHF

Addex Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 12:13 AM
 
REVENUEM CHF
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CHF
EBITM CHF
EBIT MARGIN%
NET INCOMEM CHF
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
–––6.002.003.003.001.001.00–––––––
––––-66.6750.00–-66.67––––––––
–––-16.67-50.00-33.33-33.33-100.00-100.00–––––––
-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00
-3.00-3.00-3.00-1.00-14.00-12.00-15.00-20.00-2.00-2.00-3.00-3.00-3.00-2.00-2.00–
–––-16.67-700.00-400.00-500.00-2,000.00-200.00–––––––
-4.00-3.00-3.00-1.00-14.00-12.00-15.00-20.00-10.007.00-7.00-4.00–-3.00––
300.00-25.00–-66.671,300.00-14.2925.0033.33-50.00-170.00-200.00-42.86––––
10.8511.4112.9423.2926.4326.6834.1245.1874.3198.1198.1198.1198.1198.1198.1198.11
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Addex Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Addex Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Addex Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Addex Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Addex Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Addex Therapeutics stock margins

The Addex Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Addex Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Addex Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-958.33 %
-315.62 %
-331.48 %
Jan 1, 2021
-958.33 %
-491.74 %
-481.97 %
Jan 1, 2022
-958.33 %
-1,420.08 %
-1,439.74 %
Jan 1, 2023
-958.33 %
-138.70 %
-652.75 %
Jan 1, 2024
-958.33 %
-672.00 %
1,720.93 %
Jan 1, 2025 (e)
-958.33 %
-432.00 %
-915.72 %
Jan 1, 2026 (e)
-958.33 %
-434.67 %
-523.27 %
Jan 1, 2027 (e)
-958.33 %
- %
0.00 %

Addex Therapeutics Stock Revenue, EBIT, Earnings per Share

The Addex Therapeutics earnings per share therefore indicates how much revenue Addex Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.15 CHF
-0.46 CHF
-0.48 CHF
Jan 1, 2021
0.09 CHF
-0.45 CHF
-0.45 CHF
Jan 1, 2022
0.03 CHF
-0.45 CHF
-0.46 CHF
Jan 1, 2023
0.02 CHF
-0.03 CHF
-0.14 CHF
Jan 1, 2024
0.00 CHF
-0.03 CHF
0.07 CHF
Jan 1, 2025 (e)
0.01 CHF
-0.03 CHF
-0.07 CHF
Jan 1, 2026 (e)
0.01 CHF
-0.03 CHF
-0.04 CHF
Jan 1, 2027 (e)
0.00 CHF
-0.03 CHF
0.00 CHF

Addex Therapeutics business model & stock analysis

Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of novel oral drugs. The company was founded in Geneva, Switzerland in 2002 and has made significant progress in researching drug candidates for various conditions such as schizophrenia, ADHD, migraines, and other central nervous system disorders. Addex Therapeutics' business model is based on the development of modulating therapeutics that specifically influence cellular signaling pathways. The company utilizes the proven AMC platform (Addex Modulation Cloning) to quickly and efficiently identify and validate specific receptor projects. Additionally, the company has a wide range of research and development programs, from preclinical to clinical study phases. Addex Therapeutics Ltd specializes in three therapeutic areas: neurological, immunological, and anti-inflammatory diseases. Within these areas, the company develops various drugs that specifically target certain receptors and provide help and relief for various conditions. One of Addex's most significant medical projects currently is the ADX71149 drug candidate for the treatment of schizophrenia and autism. Addex Therapeutics Ltd's products include a variety of neuromodulators and other drug candidates. The company has filed numerous international patents and maintains a high standard in the pharmaceutical development industry. The key product candidates are: - ADX10059: A new drug used in the treatment of migraines and dizziness. ADX10059 is a P2X3 receptor antagonist that can help suppress the transmission of pain signals in the central nervous system. - ADX88178: A drug candidate targeting the GABA-B receptor. This receptor is central to deep-seated pain and extrapyramidal side effects of classic antipsychotics. - ADX71943: A drug candidate used in the treatment of neuropsychiatric disorders such as Rett syndrome and ADHD. ADX71943 is a selective agonist of the GABA-B receptor, modulating the release of neurotransmitters in the brain. Overall, Addex Therapeutics offers an extensive product range and carries out a variety of projects in different stages of development. The company's core competency lies in modulators that can control specific receptors (neurotransmitter or hormone receptors). Addex Therapeutics Ltd is headquartered in Geneva, Switzerland, but also has branches in New York and San Francisco. The company focuses on expanding its competitiveness in the field of novel drugs and expanding its portfolio of products and international customers.

Addex Therapeutics SWOT Analysis

Strengths

Addex Therapeutics Ltd possesses several strengths that contribute to its competitive advantage in the pharmaceutical industry. These strengths include:

  • Strong Research and Development (R&D) capabilities, leading to a robust pipeline of innovative drug candidates.
  • Diverse and experienced team of scientists and professionals, driving innovation and enabling efficient drug development.
  • Strategic partnerships and collaborations with leading pharmaceutical companies, enhancing resources and expertise.
  • Efficient and cost-effective production processes, enabling competitive pricing and faster time-to-market.

Weaknesses

Despite its strengths, Addex Therapeutics Ltd also faces certain weaknesses that may hinder its growth and market position. These weaknesses include:

  • Relatively small scale compared to well-established pharmaceutical giants, limiting brand recognition and market penetration.
  • Limited financial resources, potentially affecting the ability to invest in R&D and marketing initiatives at the same scale as competitors.
  • Dependency on successful clinical trials for drug approvals, exposing the company to potential setbacks and delays.
  • Reliance on key partnerships and collaborations, making the company vulnerable to changes or termination of these relationships.

Opportunities

Addex Therapeutics Ltd can leverage various opportunities in the pharmaceutical market to further strengthen its position and drive growth. These opportunities include:

  • Increasing demand for novel and targeted treatments, especially in areas with limited treatment options.
  • Emerging markets with growing healthcare infrastructures and access to innovative therapies.
  • Advancements in technology, such as precision medicine and gene therapies, providing new avenues for drug development.
  • Increasing focus on personalized medicine, allowing Addex Therapeutics Ltd to tailor treatments to specific patient populations.

Threats

Several threats pose challenges to Addex Therapeutics Ltd's sustainability and profitability. These threats include:

  • Intense competition from larger pharmaceutical companies with extensive resources and established market presence.
  • Rapidly evolving regulatory environment, presenting hurdles in obtaining approvals and complying with changing regulations.
  • Economic downturns and fluctuations in healthcare spending, impacting affordability and market demand for pharmaceutical products.
  • Potential intellectual property infringements and patent expirations, leading to generic competition and revenue loss.

Addex Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Addex Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Addex Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Addex Therapeutics shares outstanding

The number of shares of Addex Therapeutics was 98.11 M in 2025. This indicates how many shares Addex Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
26.68 M Stocks
Jan 1, 2021
34.12 M Stocks
Jan 1, 2022
45.18 M Stocks
Jan 1, 2023
74.31 M Stocks
Jan 1, 2024
98.11 M Stocks
Jan 1, 2025 (e)
98.11 M Stocks
Jan 1, 2026 (e)
98.11 M Stocks
Jan 1, 2027 (e)
98.11 M Stocks

Current Addex Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
20.00 % (2)
Sell
80.00 % (8)
12M Price Target
0.16
Last Price
0.04
Currency
CHF
12M Return Potential
316.33 %
LTM Return
0 %

Addex Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
9/17/2013-0.64CHF-84,579.00CHF-2013 Q2
2/28/2013-1.61CHF-710,499.00CHF-2012 Q4
8/22/2012-1.94CHF-304,499.00CHF-2012 Q2
2/23/2010-4.11CHF-1.67 MCHF-2009 Q4
7/28/2009-3.68CHF-2.03 MCHF-2009 Q2
2/24/2009-4.81CHF-2.08 MCHF-2008 Q4
9/11/2008-2.24CHF-20.76 MCHF-2008 Q2

EESG©

Eulerpool ESG Scorecard© for the Addex Therapeutics stock

28/100
33
Environment
14
Social
38
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Addex Therapeutics shareholder structure

% Name
17.17307%
Dyer (Timothy)
Dyer (Timothy)
1.36211%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG
0.51268%
UBS Asset Management (Switzerland)
UBS Asset Management (Switzerland)
0.30589%
Banque Lombard Odier & Cie SA
Banque Lombard Odier & Cie SA
0.14191%
Zürcher Kantonalbank (Asset Management)
Zürcher Kantonalbank (Asset Management)
0.07451%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited

Addex Therapeutics Executives and Management Board

8 members · avg. age 60 · 0 % women

TD

Mr. Tim Dyer (57)

Chief Executive Officer, Co-Founder, Member of the Executive Management, Director

3.65 M CHF

Management

RM

Dr. Roger Mills (68)

Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors · since 2016

27,749.00 CHF
MK

Dr. Mikhail Kalinichev (58)

Member of the Executive Management, Head of Translational Science

–
LT

Mr. Lenaic Teyssedou (40)

Member of the Executive Management, Head of Finance

–

Board of Directors

VL

Dr. Vincent Lawton (76)

Independent Non-Executive Chairman of the Board of Directors

76,857.00 CHF
RH

Dr. Raymond Hill (80)

Non-Executive Independent Member of the Board of Directors

46,279.00 CHF
IM

Dr. Isaac Manke (48)

Non-Executive Independent Member of the Board of Directors

34,597.00 CHF
JN

Mr. Jake Nunn (55)

Non-Executive Independent Member of the Board of Directors

34,597.00 CHF

Addex Therapeutics Supply Chain

Addex Therapeutics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
Indivior
Supplier·Customer·Pharmaceuticals·GB
-0.20
0.31
-0.64
-0.65
-0.87
-0.83
2
Johnson & Johnson
Supplier·Customer·Pharmaceuticals·US
0.55
0.06
-0.74
-0.69
-0.33
-0.61
3
Goldman Sachs Group
Supplier·Customer·Capital Markets·US
0.47
0.53
0.75
0.91
0.64
-0.53

Frequently asked questions about Addex Therapeutics

The business model of Addex Therapeutics Ltd revolves around developing novel oral small molecules for diseases that are currently not well-treated or have a significant unmet medical need. They focus on targeting specific proteins in the central nervous system (CNS) to address therapeutic gaps within neurological disorders and addiction-related diseases. Addex Therapeutics utilizes its proprietary drug discovery platform, allosteric modulation technology, to create innovative therapies. By leveraging their expertise, Addex Therapeutics aims to bring forth effective and safe treatment options to improve patients' lives and generate value for their shareholders.

Addex Therapeutics Ltd is primarily active in the pharmaceutical industry.

The main competitors of Addex Therapeutics Ltd in the market are other biopharmaceutical companies involved in the development and commercialization of novel therapies and treatments targeting similar disease areas. Some key competitors include AbbVie Inc., Alkermes plc, Eli Lilly and Company, and Johnson & Johnson.

Addex Therapeutics Ltd is a biopharmaceutical company with a rich history and background in the field of neuroscience. Founded in 2002, Addex has constantly been working towards the development of innovative therapeutic solutions for diseases such as Parkinson's and Schizophrenia. The company has a strong focus on modulating specific receptors in the brain to target and treat these conditions. With a dedicated team of scientists and researchers, Addex Therapeutics has made significant advancements in drug discovery and has several promising compounds in its pipeline. The company's commitment to improving the lives of patients and its relentless pursuit of groundbreaking therapies has positioned Addex as a leading player in the biopharmaceutical industry.

Addex Therapeutics Ltd has achieved significant milestones in its industry. The company successfully developed and advanced its allosteric modulator drugs, targeting various diseases such as Parkinson's disease and schizophrenia. Addex Therapeutics also achieved notable progress in its clinical development programs, conducting successful Phase II trials for its lead candidate, dipraglurant, in Parkinson's disease levodopa-induced dyskinesia. The company has further strengthened its position through collaborations with industry-leading partners to expedite the development and commercialization of its innovative therapies. With its commitment to scientific excellence and strong pipeline, Addex Therapeutics Ltd continues to make remarkable strides in the field of allosteric modulation for the benefit of patients and investors.

Addex Therapeutics Ltd is primarily present in multiple countries and regions worldwide. The company has a global presence with a focus on key markets such as the United States, Europe, and Asia. By expanding its reach across these regions, Addex Therapeutics Ltd aims to maximize its market potential and cater to a diverse range of customers. With its presence in multiple countries and regions, Addex Therapeutics Ltd is well-positioned to capitalize on emerging opportunities and strengthen its position as a leading player in the pharmaceutical industry.

Addex Therapeutics Ltd represents a set of core values and a corporate philosophy that guide its operations. The company is committed to scientific excellence, innovation, and patient-centricity in the field of drug discovery and development. Addex Therapeutics strives to improve the lives of patients by developing novel oral small molecules targeting specific biological pathways. With a focus on therapeutic areas such as neurology and immunology, the company aims to deliver innovative solutions to unmet medical needs. By fostering collaboration and leveraging its expertise, Addex Therapeutics is dedicated to advancing the frontiers of medicine and bringing transformative therapies to patients worldwide.

Analysts currently set an average price target of 0.16 CHF for the Addex Therapeutics stock (median: 0.16 CHF), implying +316.3 % versus the latest price. The consensus is based on 10 analyst ratings.

Addex Therapeutics Analyst Price Targets 2026

9 analysts currently rate the Addex Therapeutics stock: 0 recommend buying, 2 holding and 7 selling. For 2026, analysts expect Addex Therapeutics to generate revenue of 765,000.00 CHF and earnings per share of -0.04 CHF.

Addex Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Addex Therapeutics share trades at 0.04 EUR (0.04 CHF).

The Addex Therapeutics share (ADXN.SW) is listed on 4 stock exchanges, including: Frankfurt (APE.F), München (APE.MU), London (0QNV.L), SIX (Zürich) (ADXN.SW).

Addex Therapeutics Ltd is a biopharmaceutical company specialized in the development of novel orally available drugs for the treatment of central nervous system diseases, as well as inflammatory and metabolic diseases. The company has developed a unique drug design and screening platform system focusing on allosteric modulators to selectively and effectively develop drugs. Addex Therapeutics operates in three main areas: clinical development programs, preclinical development programs, and partnerships with third parties. In the clinical development programs, Addex Therapeutics has various drug candidates in clinical development or near the start of clinical trials. The company works closely with contract research organizations to conduct these studies and ensure the safety and efficacy of the drug candidates. Addex Therapeutics' clinical development programs include the following drug classes: - ADX10059: A calcium channel modulator that offers an alternative therapy for the treatment of chronic migraine and gastroesophageal reflux disease. - ADX71149: A GABAB receptor modulator that represents a potential treatment option for schizophrenia and alcoholism. - ADX71441: A G-protein coupled receptor modulator that represents a potential treatment option for anxiety disorders. In the preclinical development programs, Addex Therapeutics is working on the development of drug candidates in the earliest phase of the development process. These drug candidates are still in early research and are being tested in vitro and in vivo to determine their potential for further development in later research stages, considering safety and efficacy. Addex Therapeutics has a wide range of technologies for drug discovery. The company utilizes various technologies to effectively shape drug design. Allosteric modulation is at the core of Addex Therapeutics' drug design system, allowing the company to selectively target specific targets within cells and tissues that play a role in various diseases. In partnerships with third parties, Addex Therapeutics collaborates with other companies or academic partners to further develop its drug candidates or develop new technologies. Addex Therapeutics has signed several agreements with leading biotech and pharmaceutical companies to expand the use of allosteric modulators. In addition to its drug candidates, Addex Therapeutics also offers drug discovery services. The company provides its customers with access to its technology platform to identify new drug candidates and accelerate drug development. These services are an important part of Addex Therapeutics' business model and contribute to the company's growth and diversification. Overall, Addex Therapeutics has a unique business model based on the development of novel drugs targeting specific targets within cells and tissues. With its technology platform and broad expertise in drug development, the company is able to efficiently and effectively navigate its drug candidates through clinical development. Addex Therapeutics' strategic partnerships and drug discovery services provide additional growth opportunities. Translation provided by a language model trained on a mixture of professional translations and publicly available data.

The expected revenue of Addex Therapeutics is 765,000.00 CHF. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Addex Therapeutics is -4.00 M CHF. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Addex Therapeutics is currently -0.96. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Addex Therapeutics stock.

The price-to-sales ratio (P/S) of Addex Therapeutics is currently 5.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Addex Therapeutics stock.

The Eulerpool Quality Score for Addex Therapeutics is 2/10.

The ISIN of Addex Therapeutics is CH0029850754. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Addex Therapeutics is A0MSH6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Addex Therapeutics is ADXN.SW. The ticker symbol is used to trade Addex Therapeutics shares on the stock exchange.

Addex Therapeutics paid dividends every year for the past 0 years.

Addex Therapeutics is assigned to the 'Health' sector.

The dividends of Addex Therapeutics are distributed in CHF.

All fundamentals and in-depth analysis of Addex Therapeutics

Our stock analysis for Addex Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Addex Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Addex Therapeutics Stock
Addex Therapeutics Revenue→
Addex Therapeutics Stock
Addex Therapeutics Net Income→
Addex Therapeutics Stock
Addex Therapeutics P/E→
Addex Therapeutics Stock
Addex Therapeutics P/S→
Addex Therapeutics Stock
Addex Therapeutics EBIT→
Addex Therapeutics Stock
Addex Therapeutics Dividend→
Addex Therapeutics Stock
Addex Therapeutics Directors Dealings→
Addex Therapeutics Stock
Addex Therapeutics Stocks→
Addex Therapeutics Stock
Addex Therapeutics Market capitalization→
Addex Therapeutics Stock
Addex Therapeutics Debt→
Addex Therapeutics Stock
Addex Therapeutics Liabilities→
Addex Therapeutics Stock
Addex Therapeutics Equity→
Addex Therapeutics Stock
Addex Therapeutics AAQS→
Addex Therapeutics Stock
Addex Therapeutics Employees→
Addex Therapeutics Stock
Addex Therapeutics ROE→
Addex Therapeutics Stock
Addex Therapeutics ROA→
Addex Therapeutics Stock
Addex Therapeutics ROCE→
Addex Therapeutics Stock
Addex Therapeutics News→
Addex Therapeutics Stock
Addex Therapeutics Analyst Price Targets→

Health Stocks

Addex TherapeuticsADC TherapeuticsAddLifeADBiotech CoAddus HomecareAdaptive BiotechnologiesAdeshwar MeditexAdapthealthAdhera TherapeuticsAdaltaAdheris HealthAdageneAll Stocks A–Z →